Tim Harkness, Unchained Labs CEO

The Car­lyle Group shells out $435M for con­trol­ling stake in vac­cine, gene ther­a­py ser­vices com­pa­ny

The Car­lyle Group has put a tar­get on life sci­ences in re­cent years, look­ing for op­por­tu­ni­ties to take con­trol­ling stakes in promis­ing firms. Af­ter shelling …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.